Fu Wei, Song Zhiqiang, Zhou Liya, Xue Yan, Ding Yu, Suo Baojun, Tian Xueli, Wang Li
Department of Gastroenterology, Peking University Third Hospital, No 49, North Garden Road, Haidian District, Beijing, 100191, China.
Dig Dis Sci. 2017 Jun;62(6):1580-1589. doi: 10.1007/s10620-017-4564-4. Epub 2017 Apr 8.
The eradication of Helicobacter pylori infection remains a challenge, especially in the patients unsuitable to take penicillin. Cephalosporin has the potential to replace amoxicillin for H. pylori eradication.
To compare the effectiveness, safety, and compliance of amoxicillin- and cefuroxime-containing quadruple regimens in treatment-naïve patients.
In this open-label randomized control study, 400 patients with H. pylori infection were divided into amoxicillin-containing (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) or cefuroxime-containing (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) quadruple therapy groups. The safety and compliance were assessed 1-3 days after eradication. Urea breath test was performed 8-12 weeks after eradication to determine treatment outcome.
The baseline data including antibiotic resistance were well matched between the two groups. The eradication rates between amoxicillin- and cefuroxime-containing quadruple therapy groups were not significantly different [intention-to-treat analysis: 83.5% (95% confidence interval 78.3-88.7%) vs. 81.0% (75.5-86.5%), P = 0.513; modified intention-to-treat analysis: 90.3% (86.0-94.6%) vs. 88.5% (83.9-93.2%), P = 0.586; per-protocol analysis: 91.6% (87.5-95.7%) vs. 89.8% (85.3-94.3%), P = 0.560]. The incidence of adverse effects (18.4 vs. 20.1%, P = 0.678) and compliance (94.7 vs. 94.2%, P = 0.813) were also similar. Variate analyses showed that antibiotic resistance and poor compliance were the independent risk factors for eradication failure.
Esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime achieved similar and relatively satisfactory cure rates, safety, and compliance in first-line H. pylori eradication. Cefuroxime may be a good alternative medicine for eradication instead of amoxicillin for the patients unsuitable to take penicillin.
根除幽门螺杆菌感染仍然是一项挑战,尤其是在不适合使用青霉素的患者中。头孢菌素有可能替代阿莫西林用于根除幽门螺杆菌。
比较含阿莫西林和含头孢呋辛的四联方案在初治患者中的有效性、安全性和依从性。
在这项开放标签随机对照研究中,400例幽门螺杆菌感染患者被分为含阿莫西林组(埃索美拉唑20mg,每日2次;阿莫西林1000mg,每日2次;左氧氟沙星500mg,每日1次;铋剂220mg,每日2次,共14天)或含头孢呋辛组(埃索美拉唑20mg,每日2次;头孢呋辛500mg,每日2次;左氧氟沙星500mg,每日1次;铋剂220mg,每日2次,共14天)的四联治疗组。在根除治疗1 - 3天后评估安全性和依从性。根除治疗8 - 12周后进行尿素呼气试验以确定治疗结果。
两组间包括抗生素耐药性在内的基线数据匹配良好。含阿莫西林和含头孢呋辛的四联治疗组之间的根除率无显著差异[意向性分析:83.5%(95%置信区间78.3 - 88.7%)对81.0%(75.5 - 86.5%),P = 0.513;改良意向性分析:90.3%(86.0 - 94.6%)对88.5%(83.9 - 93.2%),P = 0.586;符合方案分析:91.6%(87.5 - 95.7%)对89.8%(85.3 - 94.3%),P = 0.560]。不良反应发生率(18.4%对20.1%,P = 0.678)和依从性(94.7%对94.2%,P = 0.813)也相似。变量分析表明抗生素耐药性和依从性差是根除失败的独立危险因素。
埃索美拉唑、铋剂、左氧氟沙星和阿莫西林或头孢呋辛在一线根除幽门螺杆菌治疗中取得了相似且相对满意的治愈率、安全性和依从性。对于不适合使用青霉素的患者,头孢呋辛可能是一种替代阿莫西林的良好根除药物。